Alpine Immune Sciences Cultura da Companhia

Dr. Jay R. Venkatesan, Ph.D., M.D. has been the President of Alpine Immune Sciences, Inc since June 2016. Dr. Venkatesan has been a Managing Partner at Alpine BioVentures, GP, LLC since July 13, 2015. He served as the President of Nivalis Therapeutics, Inc. since July 24, 2017. Dr. Venkatesan was the Co-Founder and served as Chief Executive Officer of Alpine Biosciences, Inc. from November 2015 to June 2016. He served as Chief Executive Officer at Alpine Immune Sciences, Inc. from November 2015 to June 2016. Dr. Venkatesan served as an Executive Vice President and General Manager of Cascadian Therapeutics, Inc. (formerly Oncothyreon Inc.) from August 11, 2014 to May 15, 2015. Previously, Dr. Venkatesan was the Founder and served as Portfolio Manager and Managing Director of Ayer Capital Management LP, a global healthcare equity fund from 2008 to December 2013. He served as an Analyst at Apax partners and McKinsey & Co. He founded Varro Technologies and served as its Chief Executive Officer. From July 1995 to August 1996, he served at Partricof & Co. Ventures, with a focus on life sciences investments and healthcare venture investing. Dr. Venkatesan leads the creation of new companies, identifies investment opportunities and collaborates with innovators to develop game-changing therapies that can meaningfully impact patients??? lives. He served at McKinsey & Company from August 1993 to June 1995, where he consulted companies in the pharmaceutical, media and information technology industries. He has been an Independent Director of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.) since September 3, 2013. He has been a Director at Alpine Immune Sciences, Inc. since June 13, 2016. He has been a Director at Exicure Inc. since March 2014. He serves on the board of CellBioTherapy, Transplant Genomics, Exicure Therapeutics, AuraSense Therapeutics. He serves as a Director of Bain Capital, LLC and Brookside Capital Management, LLC. He served as a Director of Nivalis Therapeutics, Inc. since July 24, 2017. He served as a Director of Brookside Capital Partners since July 2002 until 2007. He served as a Director of REVA Medical, Inc. He served as a Director of Targanta Therapeutics, Corp. from January 2007 to August 25, 2008. Dr. Venkatesan holds an M.D. from the University Of Pennsylvania School Of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and has received a B.A. in Chemistry from Williams College, where he was elected to Phi Beta Kappa.

Mr. Paul Rickey has been the Chief Financial Officer and Senior Vice President of Alpine Immune Sciences Inc. since April 2017. Mr. Rickey is an experienced executive who has spent nearly 16 years guiding financial strategy in the life sciences and technology industries. Mr. Rickey served as the Chief Financial Officer, Senior Vice President and Secretary at Nivalis Therapeutics, Inc. since July 24, 2017. He served as the Chief Financial Officer of Sound Pharmaceuticals, Inc. from March 1, 2016 to April 6, 2017. He served as Vice President of Finance and Administration of Immune Design Corp., where he helped complete its private offerings, initial public offering and follow-on financing. In addition, he oversaw the finance, accounting and human resource functions through July 2015. Before joining Immune Design in 2009, he was Corporate Controller of Northstar Neuroscience, a publicly traded medical device company, where he managed its finance and accounting groups following their IPO. Prior to his role at Northstar Neuroscience, he served as an Accounting Manager for Mobliss, Inc., a mobile technology company that was sold to Index Corp., of Japan. He started his career at Ernst & Young LLP. Mr. Rickey graduated from the University of Washington with a BA and Masters in Professional Accounting and is a Certified Public Accountant.

Mr. Ryan Swanson co-founded Alpine Immune Sciences Inc. in 2015 and served as its Vice President of Immunology until December 14, 2017. Mr. Swanson leveraged sixteen years of discovery research experience at five different northwest biotech companies. He has broad exposure to developing biologic therapeutics targeted at the human immune system in his roles at sIgA Pharmaceuticals, Cell Therapeutics, Corixa, ICOS and Amgen. His recent publication on the relatively new Butyrophilin family of costimulatory molecules represents his expertise on using both activating and inhibitory costimulatory molecules to program T cells in an effort to modulate human disease. He is well-versed in developing novel recombinant platforms to facilitate or disrupt multi-protein interactions in generating meaningful biological activity that is unique in the industry today.

Dr. Stanford Peng, M.D., Ph.D., has been the Chief Medical Officer and Executive Vice President of Research & Development at Alpine Immune Sciences Inc. since September 15, 2016. Dr. Peng served as Executive Vice President of Research & Development and Chief Medical Officer at Nivalis Therapeutics, Inc. since July 24, 2017. He has extensive experience in immunology, rheumatology and oncology drug development to lead AIS??? development of protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune disorders and other serious diseases. He has more than 16 years of clinical and basic biomedical research experience in multiple settings, including large pharma, startups, biotech and clinical practice. He served as the Chief Medical Officer of Stemcentrx, Inc. from April 1, 2016 to September 15, 2016 and was responsible for its translational and clinical development activities. He served as the Head of Clinical Development and Vice President of Stemcentrx, Inc. from 2015 to April 1, 2016. He served as an Executive Medical Director and Head of Inflammation & Translational Medicine at Seattle Genetics. He served as the Head of the Rheumatology Clinical Research Unit and Clinical Associate Member at the Benaroya Research Institute in Seattle from 2009 to 2014, where he served as the Director of Autoimmunity-Related Clinical Trials and Translational Research. He held clinical positions as a Member Physician at Virginia Mason Medical Center in Seattle between 2009 and 2014 and as an Assistant Professor in the Division of Rheumatology at the Washington University School of Medicine from 2002 to 2005. He served as Senior Director of Clinical Research and Exploratory Development at Roche Pharmaceuticals from 2005 to 2008. From 2008 to 2009, Dr. Peng served as Senior Director at ARYx Therapeutics, Inc. He served as Translational Medical Leader of the Inflammation Disease Biology Area. He completed his Residency in Internal Medicine at the Hospital of the University of Pennsylvania School of Medicine in Philadelphia, followed by a Clinical and Research Fellowship in Rheumatology at Brigham and Women's Hospital in Boston. Dr. Peng received an M.D. and Ph.D. in Biology from the Yale University School of Medicine and a B.A. in music and B.S. in Biological Sciences from Stanford University.

Stanford Peng serves as the EVP, Research & Development and Chief Medical Officer of Alpine Immune Sciences, Inc.. Stanford currently resides in the Greater Seattle Area.

Mark Litton serves as the President and Chief Operating Officer of Alpine Immune Sciences, Inc.. Mark currently resides in the Greater Seattle Area.

Kristi Manjarrez serves as the Vice President, Clinical Affairs of Alpine Immune Sciences, Inc.. Kristi currently resides in the Greater Seattle Area.